ArticleJournal of thrombosis and thrombolysis2021
Lupus anticoagulant and mortality in patients hospitalized for COVID-19.
Article in Journal of thrombosis and thrombolysis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 4 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Antiphospholipid antibodies in patients with COVID-19: a systematic review and meta-analysis.Journal of thrombosis and thrombolysis · 2025Pooled it
- Antiphospholipid antibody-related hepatic vasculitis in a juvenile after non-severe COVID-19: a case report and literature review.Frontiers in immunology · 2024Pooled it
- Pooled it
- Systematic Review of Antiphospholipid Antibodies in COVID-19 Patients: Culprits or Bystanders?Current rheumatology reports · 2021Pooled it
- Effects of antiphospholipid antibodies in the severity and outcome of COVID-19.BMC infectious diseases · 2026Article
- Chilblain-like lesion associated with coronavirus disease 2019 vaccine in tropical country: a case report.Journal of medical case reports · 2025Article
- A cluster of pediatric vaccine-induced immune thrombotic thrombocytopenia-like cases with thrombosis and thrombocytopenia following respiratory infections-case series.Research and practice in thrombosis and haemostasis · 2024Article
- Antiphospholipid Antibodies and Vascular Thrombosis in Patients with Severe Forms of COVID-19.Biomedicines · 2023Article
- Assessment of COVID -19 associated coagulopathy and multiple hemostatic markers: a single center study in Egypt.Infection · 2023Article
- Lupus anticoagulants as a prospective independent predictor in COVID-19 patients.International journal of laboratory hematology · 2023Article
- COVID-19 and the antiphospholipid syndrome.Autoimmunity reviews · 2022Review
- Molecular mimicry, hyperactive immune system, and SARS-COV-2 are three prerequisites of the autoimmune disease triangle following COVID-19 infection.International immunopharmacology · 2022Review
- COVID-19 and antiphospholipid antibodies.Best practice & research. Clinical haematology · 2022Review
- [Assessment of antiphospholipid antibodies during the follow-up of patients after SARS-CoV-2 infection].Medicina clinica · 2022Article
- Engineering viral genomics and nano-liposomes in microfluidic platforms for patient-specific analysis of SARS-CoV-2 variants.Theranostics · 2022Review
- Platelets in the perspective of COVID-19; pathophysiology of thrombocytopenia and its implication as prognostic and therapeutic opportunity.International immunopharmacology · 2021Review
- Review
- Immunotoxic role of organophosphates: An unseen risk escalating SARS-CoV-2 pathogenicity.Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association · 2021Review
- Incidence of lupus anticoagulant in hospitalized covid-19 patients.American journal of blood research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus disease 2019 (COVID-19) is characterized by a procoagulant state that can lead to fatal thromboembolic events. Several studies have documented a high prevalence of lupus anticoagulant that may at least partially explain the procoagulant profile of COVID-19. However, the association between lupus anticoagulant and thrombotic complications in COVID-19 is controversial and no study has specifically evaluated the impact of lupus anticoagulant on mortality. The aim of our study was to investigate the association between lupus anticoagulant and mortality in a large group of 192 consecutive patients hospitalized for COVID-19. Lupus anticoagulant was found in 95 patients (49.5%). No difference in the percentage of patients with lupus anticoagulant was observed between 130 survivors and 62 non-survivors (47.7 versus 53,2%; p = 0.4745). When the combined outcome of death or need for mechanical ventilation in survivors was taken into account, the difference in the prevalence of patients with lupus anticoagulant between the patients with the combined outcome (n = 76) and survivors who did not require mechanical ventilation (n = 116) was not significant (52.6% versus 47.4%; p = 0.4806). In multivariate analysis predictors of mortality or need for mechanical ventilation in survivors were obesity, low oxygen saturation and elevated troponin levels measured on admission. In conclusion, our study did not show any association of lupus anticoagulant with mortality and with need for mechanical ventilation in survivors. The role of obesity, low SaO2 and elevated troponin levels as predictors of a worse prognosis in patients hospitalized for COVID-19 was confirmed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.